SIGMAR1 antibody [N1C3]
GTX115389
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetSIGMAR1
Overview
- SupplierGeneTex
- Product NameSIGMAR1 antibody [N1C3]
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1.24 mg/ml
- ConjugateUnconjugated
- Gene ID10280
- Target nameSIGMAR1
- Target descriptionsigma non-opioid intracellular receptor 1
- Target synonymsALS16, DSMA2, HMNR2, OPRS1, SIG-1R, SR-BP, SR-BP1, SRBP, hSigmaR1, sigma1R, sigma non-opioid intracellular receptor 1, SR31747 binding protein 1, aging-associated gene 8 protein, sigma 1-type opioid receptor
- HostRabbit
- IsotypeIgG
- Protein IDQ99720
- Protein NameSigma non-opioid intracellular receptor 1
- Scientific DescriptionThis gene encodes a receptor protein that interacts with a variety of psychotomimetic drugs, including cocaine and amphetamines. The receptor is believed to play an important role in the cellular functions of various tissues associated with the endocrine, immune, and nervous systems. As indicated by its previous name, opioid receptor sigma 1 (OPRS1), the product of this gene was erroneously thought to function as an opioid receptor; it is now thought to be a non-opioid receptor. Alternative splicing of this gene results in transcript variants encoding distinct isoforms. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Yeh CH, Chen J, Zheng G, et al. Novel Pyropheophorbide Phosphatydic Acids Photosensitizer Combined EGFR siRNA Gene Therapy for Head and Neck Cancer Treatment. Pharmaceutics. 2021,13(9). doi: 10.3390/pharmaceutics13091435Read this paper
- Rennekamp AJ, Huang XP, Wang Y, et al. σ1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol. 2016,12(7):552-8. doi: 10.1038/nchembio.2089Read this paper
- Lecaros RL, Huang L, Lee TC, et al. Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. Mol Ther. 2016,24(1):106-16. doi: 10.1038/mt.2015.169Read this paper
- Chen WH, Lecaros RL, Tseng YC, et al. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett. 2015,359(1):65-74. doi: 10.1016/j.canlet.2014.12.052Read this paper





